Mineralys Therapeutics, Inc.

As of October 3, 2025, Mineralys Therapeutics, Inc. shows a mildly bullish trend with mixed signals from technical indicators, having returned 30.12% over the past month and 209.18% year-to-date, despite some bearish indicators like the RSI and KST.

As of September 2, 2025, Mineralys Therapeutics, Inc. has a bullish technical trend with strong indicators, despite a bearish weekly RSI, and has significantly outperformed the S&P 500 with a year-to-date return of 223.88% compared to 12.22%.

As of June 10, 2025, Mineralys Therapeutics, Inc. has a mildly bullish trend, supported by daily moving averages and weekly Bollinger Bands, but caution is advised due to mildly bearish signals from the weekly MACD and Dow Theory.

Mineralys Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $42 million and a market cap of $898.12 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -55.19%.

As of Jun 18, Mineralys Therapeutics, Inc. has a market capitalization of 898.12 million and reported net sales of 0.00 million with a net profit of -188.51 million over the latest four quarters. Shareholder's funds were 191.26 million, and total assets amounted to 205.90 million as of Dec 24.